Ali Asif (CIK 1921163) reported 16 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-04-21). Recent activity: Sell PTGX (1,750 shares), Buy PTGX (19,500 shares), Buy PTGX (5,265 shares), Sell PTGX (24,765 shares), Sell PTGX (28,000 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-21 | Protagonist Therapeutics, Inc (PTGX) | Chief Financial Officer | Sell | 1,750 | $184,572 |
| 2026-03-27 | Protagonist Therapeutics, Inc (PTGX) | Chief Financial Officer | Buy | 19,500 | $374,205 |
| 2026-03-27 | Protagonist Therapeutics, Inc (PTGX) | Chief Financial Officer | Buy | 5,265 | $64,075 |
| 2026-03-27 | Protagonist Therapeutics, Inc (PTGX) | Chief Financial Officer | Sell | 24,765 | $2.6M |
| 2026-01-27 | Protagonist Therapeutics, Inc (PTGX) | Chief Financial Officer | Sell | 28,000 | $2.3M |
| 2026-01-27 | Protagonist Therapeutics, Inc (PTGX) | Chief Financial Officer | Buy | 16,000 | $307,040 |
| 2026-01-27 | Protagonist Therapeutics, Inc (PTGX) | Chief Financial Officer | Buy | 12,000 | $146,040 |
| 2026-01-27 | Protagonist Therapeutics, Inc (PTGX) | Chief Financial Officer | Sell | 18,203 | $1.5M |
| 2026-01-21 | Protagonist Therapeutics, Inc (PTGX) | Chief Financial Officer | Sell | 8,588 | $708,338 |
| 2026-01-06 | Protagonist Therapeutics, Inc (PTGX) | Chief Financial Officer | Buy | 25,600 | $0 |
| 2025-04-23 | Protagonist Therapeutics, Inc (PTGX) | Chief Financial Officer | Sell | 1,756 | $80,776 |
| 2025-03-14 | Protagonist Therapeutics, Inc (PTGX) | Chief Financial Officer | Buy | 15,203 | $185,021 |
| 2025-03-14 | Protagonist Therapeutics, Inc (PTGX) | Chief Financial Officer | Buy | 9,700 | $186,143 |
| 2025-03-14 | Protagonist Therapeutics, Inc (PTGX) | Chief Financial Officer | Sell | 24,903 | $1.5M |
| 2025-01-17 | Protagonist Therapeutics, Inc (PTGX) | Chief Financial Officer | Sell | 1,317 | $0 |
| 2025-01-17 | Protagonist Therapeutics, Inc (PTGX) | Chief Financial Officer | Sell | 2,601 | $0 |
Source: SEC Form 4 filings · as of 2026-04-21